These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 9223567)

  • 1. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites.
    Sutton D; Butler AM; Nadin L; Murray M
    J Pharmacol Exp Ther; 1997 Jul; 282(1):294-300. PubMed ID: 9223567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
    Butler AM; Murray M
    J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced inhibition of microsomal cytochrome P450 3A2 in rat liver during diltiazem biotransformation.
    Murray M; Butler AM
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1447-52. PubMed ID: 8968370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
    Jones DR; Gorski JC; Hamman MA; Mayhew BS; Rider S; Hall SD
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
    Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ
    J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.
    Yamazaki H; Shimada T
    Drug Metab Dispos; 1998 Nov; 26(11):1053-7. PubMed ID: 9806945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.
    Yamaori S; Yamazaki H; Iwano S; Kiyotani K; Matsumura K; Honda G; Nakagawa K; Ishizaki T; Kamataki T
    Drug Metab Pharmacokinet; 2004 Apr; 19(2):120-9. PubMed ID: 15499178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes.
    Crewe HK; Ellis SW; Lennard MS; Tucker GT
    Biochem Pharmacol; 1997 Jan; 53(2):171-8. PubMed ID: 9037249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism.
    Mei Q; Tang C; Assang C; Lin Y; Slaughter D; Rodrigues AD; Baillie TA; Rushmore TH; Shou M
    J Pharmacol Exp Ther; 1999 Nov; 291(2):749-59. PubMed ID: 10525096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.
    Eagling VA; Tjia JF; Back DJ
    Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol.
    Pan LP; De Vriendt C; Belpaire FM
    Pharmacogenetics; 1998 Oct; 8(5):383-9. PubMed ID: 9825830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of propofol on human hepatic microsomal cytochrome P450 activities.
    McKillop D; Wild MJ; Butters CJ; Simcock C
    Xenobiotica; 1998 Sep; 28(9):845-53. PubMed ID: 9764927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes.
    Berthou F; Dreano Y; Belloc C; Kangas L; Gautier JC; Beaune P
    Biochem Pharmacol; 1994 May; 47(10):1883-95. PubMed ID: 8204106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
    Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD
    J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily.
    Rodrigues AD; Roberts EM; Mulford DJ; Yao Y; Ouellet D
    Drug Metab Dispos; 1997 May; 25(5):623-30. PubMed ID: 9152603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.
    Yamazaki H; Inoue K; Shaw PM; Checovich WJ; Guengerich FP; Shimada T
    J Pharmacol Exp Ther; 1997 Nov; 283(2):434-42. PubMed ID: 9353355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4.
    Gallagher EP; Kunze KL; Stapleton PL; Eaton DL
    Toxicol Appl Pharmacol; 1996 Dec; 141(2):595-606. PubMed ID: 8975785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs.
    Venkatakrishnan K; von Moltke LL; Greenblatt DJ
    J Clin Pharmacol; 1999 Jun; 39(6):567-77. PubMed ID: 10354960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azide inhibits human cytochrome P -4502E1, 1A2, and 3A4.
    Salmela KS; Tsyrlov IB; Lieber CS
    Alcohol Clin Exp Res; 2001 Feb; 25(2):253-60. PubMed ID: 11236840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desacetyl-diltiazem displays severalfold higher affinity to CYP2D6 compared with CYP3A4.
    Molden E; Asberg A; Christensen H
    Drug Metab Dispos; 2002 Jan; 30(1):1-3. PubMed ID: 11744603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.